--- title: "Attovia Therapeutics (NASDAQ:ATTO) Releases Earnings Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/297829995.md" description: "Attovia Therapeutics (NASDAQ:ATTO) reported a quarterly EPS of ($4.88). Shares rose $0.91 to $23.13, with volume below average. Five analysts initiated coverage on Monday, assigning Buy or Outperform ratings with price targets ranging from $30 to $52, resulting in an average consensus target of $42.20. Additionally, major shareholder Redmile Group and Director Colin Walsh purchased significant shares totaling over $11 million on August 6." datetime: "2026-09-02T20:56:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297829995.md) - [en](https://longbridge.com/en/news/297829995.md) - [zh-HK](https://longbridge.com/zh-HK/news/297829995.md) generator: "portal-rs" --- # Attovia Therapeutics (NASDAQ:ATTO) Releases Earnings Results Attovia Therapeutics (NASDAQ:ATTO - Get Free Report) posted its earnings results on Wednesday. The company reported ($4.88) earnings per share for the quarter, Zacks reports. Get **Attovia Therapeutics** alerts: ## Attovia Therapeutics Stock Performance Shares of NASDAQ ATTO traded up $0.91 during mid-day trading on Wednesday, reaching $23.13. The company had a trading volume of 81,161 shares, compared to its average volume of 262,593. Attovia Therapeutics has a one year low of $16.15 and a one year high of $24.32. ## Analyst Ratings Changes A number of equities analysts recently commented on ATTO shares. Leerink Partners assumed coverage on shares of Attovia Therapeutics in a research report on Monday. They set an "outperform" rating and a $52.00 price target on the stock. Citigroup started coverage on shares of Attovia Therapeutics in a research report on Monday. They set a "buy" rating and a $30.00 target price on the stock. Lifesci Capital started coverage on shares of Attovia Therapeutics in a report on Monday. They set an "outperform" rating and a $45.00 target price on the stock. Morgan Stanley started coverage on shares of Attovia Therapeutics in a research report on Monday. They issued an "overweight" rating and a $39.00 price target for the company. Finally, Royal Bank Of Canada assumed coverage on Attovia Therapeutics in a research note on Monday. They issued an "outperform" rating and a $45.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Attovia Therapeutics currently has an average rating of "Buy" and a consensus target price of $42.20. **Get Our Latest Stock Analysis on ATTO** ## Insider Buying and Selling at Attovia Therapeutics In other news, major shareholder Redmile Group, Llc bought 200,000 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $3,400,000.00. Following the transaction, the insider owned 982,854 shares of the company's stock, valued at $16,708,518. This represents a 25.55% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Colin Walsh purchased 500,000 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the acquisition, the director owned 3,020,632 shares in the company, valued at $51,350,744. This trade represents a 19.84% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 2,740,587 shares of company stock valued at $47,269,979 over the last three months. ## Attovia Therapeutics Company Profile (Get Free Report) Attovia Therapeutics, Inc NASDAQ: ATTO is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs. Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. ## Featured Articles - Five stocks we like better than Attovia Therapeutics - Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors - J.M. Smucker Stock's Rally Has More Than Tariffs Behind It - Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? - GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Attovia Therapeutics Right Now? Before you consider Attovia Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Attovia Therapeutics wasn't on the list. While Attovia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ATTO.US](https://longbridge.com/en/quote/ATTO.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [SJM.US](https://longbridge.com/en/quote/SJM.US.md) - [WEN.US](https://longbridge.com/en/quote/WEN.US.md) - [GTLB.US](https://longbridge.com/en/quote/GTLB.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) ## Related News & Research - [Attovia Therapeutics (NASDAQ:ATTO) Upgraded by Royal Bank Of Canada to "Moderate Buy" Rating](https://longbridge.com/en/news/297636916.md) - [Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27](https://longbridge.com/en/news/297941843.md) - [Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th](https://longbridge.com/en/news/298168859.md) - [Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway](https://longbridge.com/en/news/297940103.md) - [ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030](https://longbridge.com/en/news/297826808.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**